LC Bead LUMI™ Press Releases
LC Bead LUMI™ press releases and related news and business articles.
February 28, 2018: BTG plc (LSE: BTG), a global specialist healthcare company, announced the first patient in Latin America in Mexico was treated with TheraSphere® – a treatment for hepatic neoplasia that delivers powerful radiation to tumour cells and minimizes the exposure to healthy tissue.
London, UK, 5 October 2017: BTG plc (LSE: BTG), the global specialist healthcare company, today announces it has acquired Roxwood Medical (“Roxwood”), an innovative provider of advanced cardiovascular specialty catheters used in the treatment of patients with severe coronary and peripheral artery disease.
BTG plc (LSE: BTG), the global specialist healthcare company, today announced a collaboration with the Society of Interventional Oncology (SIO), a global organization working to nurture and support interventional oncology worldwide, to explore the role of interventional oncology alongside immuno-oncology
BTG plc (LSE: BTG), the global specialist healthcare company, today announces the inclusion of treatment with PneumRx® Coils in guidelines for the management of chronic obstructive pulmonary disease (COPD) published by the Global Initiative for Chronic Obstructive Lung Disease (GOLD).
Les microsphères radio-opaques à élution médicamenteuse DC Bead LUMIMC offrent aux radiologistes interventionnels du Canada un traitement de nouvelle génération pour les patients atteints d’un cancer du foie
BTG plc (LSE: BTG), an international specialist healthcare company, today announced that the first patient in Malaysia was treated with TheraSphere™ – a transarterial radioembolisation (TARE) therapy, which targets primary liver cancer and metastatic colorectal cancer with a powerful dose of radiation while minimising exposure to healthy tissue.
BTG plc (LSE: BTG), an international specialist healthcare company, with Mirada Medical Ltd, a leading global brand in medical imaging software, today announced CE Mark certification for Simplicit90Y™ dosimetry software, designed to optimise the planning of 90Y selective internal radiation therapy (SIRT) and facilitate personalised treatment for patients with liver cancer. CE Mark certification follows approval for Simplicit90Y™ in Canada.
BTG plc (LSE: BTG), an international specialist healthcare company, today announced the launch of the BETA™ Radiation Safety Programme, a new initiative designed to reduce the risk of radiation exposure when performing selective internal radiation therapy (SIRT) with 90Y microspheres. Developed in collaboration with global experts, including Professor Jacob Kamen of the Mount Sinai Medical Center, the βETA™ Radiation Safety Programme analyses current practise and exposure risk, and provides recommendations to improve safety for healthcare professionals and patients.
BTG plc (LSE: BTG), a global specialist healthcare company, today announced that it has obtained European Conformity (CE) Mark from the Notified Body British Standards Institution (BSI) following completion of the reclassification of DC Bead® and DC BeadM1TM as Class III medical devices under Rule 8 of Annex IX to Directive 93/42/EEC.
BTG completes the acquisition of Galil Medical